{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:09:32Z","timestamp":1779221372391,"version":"3.51.4"},"reference-count":258,"publisher":"Elsevier","isbn-type":[{"value":"9780443345210","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019274","name":"National Institute of Mental Health and Neurosciences","doi-asserted-by":"publisher","award":["R01AG060610"],"award-info":[{"award-number":["R01AG060610"]}],"id":[{"id":"10.13039\/100019274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.apcsb.2025.10.002","type":"book-chapter","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:47:32Z","timestamp":1762346852000},"page":"225-265","source":"Crossref","is-referenced-by-count":0,"title":["Antibodies targeting amyloid-\u03b2 and Tau oligomers in Alzheimer\u2019s disease"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-2129","authenticated-orcid":false,"given":"Subashchandrabose","family":"Chinnathambi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagaraj","family":"Rangappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhura","family":"Chandrashekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib2","series-title":"Alzheimer\u2019s disease fact sheet","author":"Aging","year":"2023"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib3","unstructured":"Aging, N.I.O. (2023b). Alzheimer\u2019s disease genetics fact sheet. National Institute on Aging. https:\/\/www.nia.nih.gov\/health\/alzheimers-causes-and-risk-factors\/alzheimers-disease-genetics-fact-sheet#:\u223c:text=Genetic%20testing%20for%20Alzheimer\u2019s%20disease,-Genetic%20tests%20are&text=In%20some%20cases%2C%20if%20a,Genetic%20Testing%20FAQ."},{"issue":"7","key":"10.1016\/bs.apcsb.2025.10.002_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41582-022-00645-6","article-title":"Early-stage alzheimer disease: Getting trial-ready","volume":"18","author":"Aisen","year":"2022","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/151979","article-title":"Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies?","volume":"2015","author":"Alavi Naini","year":"2015","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: A comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"Journal of Nanobiotechnology"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib7","article-title":"Tau post-translational modifications: Dynamic transformers of tau function, degradation, and aggregation","volume":"11","author":"Alquezar","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s41983-024-00845-5","article-title":"Unraveling Alzheimer\u2019s: The promise of aducanumab, lecanemab, and donanemab","volume":"60","author":"Ameen","year":"2024","journal-title":"The Egyptian Journal of Neurology, Psychiatry and Neurosurgery"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043754","article-title":"Alzheimer\u2019s disease: An updated overview of its genetics","volume":"24","author":"Andrade-Guerrero","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.10.002_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.mcna.2018.10.009","article-title":"The alzheimer\u2019s disease clinical spectrum: Diagnosis and management","volume":"103","author":"Atri","year":"2019","journal-title":"The Medical Clinics of North America"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1582-4934.2007.00214.x","article-title":"Tau kinases and phosphatases","volume":"12","author":"Avila","year":"2008","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"1-4","key":"10.1016\/bs.apcsb.2025.10.002_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000334761","article-title":"Apolipoprotein E4 and brain White matter integrity in Alzheimer\u2019s disease: Tract-based spatial statistics study under 3-Tesla MRI","volume":"10","author":"Bagepally","year":"2012","journal-title":"Neuro-degenerative Diseases"},{"issue":"9770","key":"10.1016\/bs.apcsb.2025.10.002_bib13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","article-title":"Alzheimer\u2019s disease","volume":"377","author":"Ballard","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12964-021-00732-z","article-title":"Methylation as a key regulator of tau aggregation and neuronal health in Alzheimer\u2019s disease","volume":"19","author":"Balmik","year":"2021","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.10.002_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2022.151202","article-title":"Inter-relationship of histone Deacetylase-6 with Tau-cytoskeletal organization and remodeling","volume":"101","author":"Balmik","year":"2022","journal-title":"European Journal of Cell Biology"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12964-021-00736-9","article-title":"The extracellular HDAC6 ZnF UBP domain modulates the actin network and post-translational modifications of tau","volume":"19","author":"Balmik","year":"2021","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"2-3","key":"10.1016\/bs.apcsb.2025.10.002_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/pmic.201400169","article-title":"Investigation of phosphoproteome in RAGE signaling","volume":"15","author":"Batkulwar","year":"2015","journal-title":"Proteomics"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib18","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3233\/JAD-180141","article-title":"Differences between women and men in incidence rates of dementia and Alzheimer\u2019s disease","volume":"64","author":"Beam","year":"2018","journal-title":"Journal of Alzheimer\u2019s Disease: JAD"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib19","article-title":"Advancements and challenges in antiamyloid therapy for Alzheimer\u2019s disease: A comprehensive review","volume":"2024","author":"Beshir","year":"2024","journal-title":"International Journal of Alzheimer\u2019s Disease"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib20","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3233\/JAD-221284","article-title":"Extracellular tau oligomers damage the axon initial segment","volume":"93","author":"Best","year":"2023","journal-title":"Journal of Alzheimer\u2019s Disease: JAD"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.10.002_bib21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00401-015-1489-x","article-title":"Abeta targets of the biosimilar antibodies of bapineuzumab, crenezumab, solanezumab in comparison to an antibody against n\u2011truncated abeta in sporadic alzheimer disease cases and mouse models","volume":"130","author":"Bouter","year":"2015","journal-title":"Acta Neuropathologica"},{"issue":"22","key":"10.1016\/bs.apcsb.2025.10.002_bib22","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer\u2019s therapeutic development: The past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib23","series-title":"Encyclopedia of movement disorders","first-page":"265","article-title":"Neurofibrillary tangles","author":"Braak","year":"2010"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib24","series-title":"Functional neurobiology of aging","first-page":"315","article-title":"Tau phosphorylation","volume":"21","author":"Bu\u00e9e","year":"2001"},{"issue":"15","key":"10.1016\/bs.apcsb.2025.10.002_bib25","doi-asserted-by":"crossref","first-page":"e1745","DOI":"10.1212\/WNL.0000000000007231","article-title":"Relative risk for alzheimer disease based on complete family history","volume":"92","author":"Cannon-Albright","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/23328940.2015.1096438","article-title":"Temperature and toxic tau in Alzheimer\u2019s disease: New insights","volume":"2","author":"Carrettiero","year":"2015","journal-title":"Temperature (Austin)"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.10.002_bib27","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/alz.12124","article-title":"An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer\u2019s disease pathogenesis: The role of APP homeostasis","volume":"16","author":"Caselli","year":"2020","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3389\/fnagi.2019.00311","article-title":"Dysfunctional mitochondria and mitophagy as drivers of Alzheimer\u2019s disease pathogenesis","volume":"11","author":"Chakravorty","year":"2019","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib29","article-title":"Novel antibody against low-n oligomers of tau protein promotes clearance of tau in cells via lysosomes","volume":"6","author":"Chandupatla","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"issue":"8","key":"10.1016\/bs.apcsb.2025.10.002_bib30","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/13803390903540315","article-title":"Diagnosis of Alzheimer\u2019s disease using neuropsychological testing improved by multivariate analyses","volume":"32","author":"Chapman","year":"2010","journal-title":"Journal of Clinical and Experimental Neuropsychology"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/hmg\/ddn326","article-title":"Dissociation of tau toxicity and phosphorylation: Role of GSK-3beta, MARK and Cdk5 in a drosophila model","volume":"18","author":"Chatterjee","year":"2009","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib32","article-title":"Comparison of explainable AI models for MRI-based Alzheimer\u2019s disease classification","author":"Chattopadhyay","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/srep41889","article-title":"Modulation of microglial cell Fc\u03b3 receptor expression following viral brain infection","volume":"7","author":"Chauhan","year":"2017","journal-title":"Scientific Reports"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.10.002_bib34","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: Structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacologica Sinica"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","article-title":"Tau and neuroinflammation in Alzheimer\u2019s disease: Interplay mechanisms and clinical translation","volume":"20","author":"Chen","year":"2023","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib36","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuroscience.2020.04.019","article-title":"G-Protein coupled receptors and Tau-different roles in Alzheimer\u2019s disease","volume":"438","author":"Chidambaram","year":"2020","journal-title":"Neuroscience"},{"issue":"10","key":"10.1016\/bs.apcsb.2025.10.002_bib37","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1080\/07391102.2020.1856720","article-title":"Role of cysteines in accelerating tau filament formation","volume":"40","author":"Chidambaram","year":"2022","journal-title":"Journal of Biomolecular Structure & Dynamics"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13578-020-00474-4","article-title":"Interaction of tau with the chemokine receptor, CX3CR1 and its effect on microglial activation, migration and proliferation","volume":"10","author":"Chidambaram","year":"2020","journal-title":"Cell & Bioscience"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib39","series-title":"Advances in protein chemistry and structural biology","doi-asserted-by":"crossref","DOI":"10.1016\/bs.apcsb.2024.08.003","article-title":"Heat shock proteins regulates tau protein aggregation in Alzheimer\u2019s disease","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib40","series-title":"Advances in protein chemistry and structural biology","article-title":"Histone deacetylase\u2019s regulates tau function in Alzheimer\u2019s disease","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib41","series-title":"Advances in protein chemistry and structural biology","article-title":"Small molecule-mediated therapeutic approaches to target tau and Alzheimer\u2019s disease","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib42","series-title":"Advances in protein chemistry and structural biology","article-title":"Tau proteotasis in Alzheimer\u2019s disease","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib43","series-title":"Advances in protein chemistry and structural biology","article-title":"Lipid role in synapse and nuclear envelope-associated endocytic pathways in tauopathy","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib44","series-title":"Advances in protein chemistry and structural biology","article-title":"Cholesterol metabolism regulates tauopathy in Alzheimer\u2019s disease","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib45","series-title":"Advances in protein chemistry and structural biology","article-title":"Apolipoprotein e and tau interaction in Alzheimer\u2019s disease","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib46","series-title":"Advances in protein chemistry and structural biology","article-title":"Nuclear transport protein suppresses tau neurodegeneration","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib47","series-title":"Advances in protein chemistry and structural biology","article-title":"Chapter fifteen - G-protein coupled receptors regulates tauopathy in neurodegeneration","volume":"vol. 141","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/bs.apcsb.2024.04.001","article-title":"G-protein coupled receptors regulates tauopathy in neurodegeneration","volume":"141","author":"Chinnathambi","year":"2024","journal-title":"Advances in Protein Chemistry and Structural Biology"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13578-023-01028-0","article-title":"Microglia degrade tau oligomers deposit via purinergic P2Y12-associated podosome and filopodia formation and induce chemotaxis","volume":"13","author":"Chinnathambi","year":"2023","journal-title":"Cell BioSciences"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.10.002_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2023.119477","article-title":"Tau aggregates improve the purinergic receptor P2Y12-associated podosome rearrangements in microglial cells","volume":"1870","author":"Chinnathambi","year":"2023","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib51","series-title":"Advances in protein chemistry and structural biology","article-title":"Chapter fourteen - the crosstalk between extracellular matrix proteins and tau","volume":"Vol. 141","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib52","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/bs.apcsb.2024.04.002","article-title":"The crosstalk between extracellular matrix proteins and tau","volume":"141","author":"Chinnathambi","year":"2024","journal-title":"Advances in Protein Chemistry and Structural Biology"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.neuroscience.2021.09.003","article-title":"Implications of Valosin-containing protein in promoting autophagy to prevent tau aggregation","volume":"476","author":"Chinnathambi","year":"2021","journal-title":"Neuroscience"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib54","series-title":"Advances in protein chemistry and structural biology","doi-asserted-by":"crossref","DOI":"10.1016\/bs.apcsb.2024.08.004","article-title":"The cross-talk between ApoE and tau protein in Alzheimer\u2019s disease","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib55","series-title":"Advances in protein chemistry and structural biology","article-title":"Medicinal chemistry-based novel herapeutics for tauopathies in Alzheimer\u2019s disease","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib56","series-title":"Advances in protein chemistry and structural biology","article-title":"Modifiable chemical risk factors for amyloid-\u03b2 and tau protein in Alzheimer\u2019s disease","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib57","series-title":"Advances in protein chemistry and structural biology","article-title":"Lipids modulates tau and amyloid-\u03b2 proteins in Alzheimer\u2019s disease","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib58","series-title":"Advances in protein chemistry and structural biology","article-title":"Tau protein structure and dynamics","author":"Chinnathambi","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib59","series-title":"Advances in protein chemistry and structural biology","article-title":"Nuclear tau accumulation in Alzheimer\u2019s disease","author":"Chinnathambi","year":"2024"},{"issue":"14","key":"10.1016\/bs.apcsb.2025.10.002_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411757","article-title":"The molecular mechanisms of neuroinflammation in Alzheimer\u2019s disease, the consequence of neural cell death","volume":"24","author":"Choi","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib61","year":"2018"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.10.002_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2014.117","article-title":"Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies","volume":"47","author":"Ciechanover","year":"2015","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.conb.2019.11.022","article-title":"Prion-like properties of tau assemblies","volume":"61","author":"Clavaguera","year":"2020","journal-title":"Current Opinion in Neurobiology"},{"issue":"14","key":"10.1016\/bs.apcsb.2025.10.002_bib64","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.neuron.2023.04.020","article-title":"Synaptic oligomeric tau in Alzheimer\u2019s disease - a potential culprit in the spread of tau pathology through the brain","volume":"111","author":"Colom-Cadena","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-981-32-9358-8_7","article-title":"Tau and axonal transport misregulation in tauopathies","volume":"1184","author":"Combs","year":"2019","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"12","key":"10.1016\/bs.apcsb.2025.10.002_bib66","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: Current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcdb.2021.12.002","article-title":"Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly","volume":"126","author":"Congdon","year":"2022","journal-title":"Seminars in Cell & Developmental Biology"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.10.002_bib68","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib69","series-title":"Preventing dementia and cognitive decline","author":"Contributors","year":"2023"},{"issue":"15","key":"10.1016\/bs.apcsb.2025.10.002_bib70","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1093\/hmg\/dds161","article-title":"Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer\u2019s diseases","volume":"21","author":"Coppola","year":"2012","journal-title":"Human Molecular Genetics"},{"issue":"10","key":"10.1016\/bs.apcsb.2025.10.002_bib71","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.4103\/1673-5374.257511","article-title":"Physiological effects of amyloid precursor protein and its derivatives on neural stem cell biology and signaling pathways involved","volume":"14","author":"Coronel","year":"2019","journal-title":"Neural Regeneration Research"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.10.002_bib72","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib73","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13195-023-01321-7","article-title":"The therapeutic landscape of tauopathies: Challenges and prospects","volume":"15","author":"Cummings","year":"2023","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/1759091420981204","article-title":"Melatonin reduces GSK3\u03b2-mediated tau phosphorylation, enhances Nrf2 nuclear translocation and anti-inflammation","volume":"12","author":"Das","year":"2020","journal-title":"ASN Neuro"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib75","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neuroscience.2020.09.024","article-title":"Actin-mediated microglial chemotaxis via G-Protein coupled purinergic receptor in Alzheimer\u2019s disease","volume":"448","author":"Das","year":"2020","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.10.002_bib76","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/tra.12784","article-title":"Microglial remodeling of actin network by tau oligomers, via g protein-coupled purinergic receptor, P2Y12R-driven chemotaxis","volume":"22","author":"Das","year":"2021","journal-title":"Traffic (Copenhagen, Denmark)"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.10.002_bib77","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice","volume":"76","author":"Demattos","year":"2012","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12964-021-00715-0","article-title":"Phosphoinositides signaling modulates microglial actin remodeling and phagocytosis in Alzheimer\u2019s disease","volume":"19","author":"Desale","year":"2021","journal-title":"Cell Communication and Signaling: CCS"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib79","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ijbiomac.2020.10.226","article-title":"\u03b1-Linolenic acid inhibits tau aggregation and modulates tau conformation","volume":"166","author":"Desale","year":"2021","journal-title":"International Journal of Biological Macromolecules"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib80","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Molecular Neurodegeneration"},{"issue":"20","key":"10.1016\/bs.apcsb.2025.10.002_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252010911","article-title":"Blood-based biomarkers in Alzheimer\u2019s disease: Advancing non-invasive diagnostics and prognostics","volume":"25","author":"Dhauria","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"Supplement_2","key":"10.1016\/bs.apcsb.2025.10.002_bib82","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/jpids\/piae036","article-title":"Understanding the regulatory pathways used to develop, evaluate, authorize, and approve new drugs and vaccines in the United States","volume":"13","author":"Domachowske","year":"2024","journal-title":"Journal of the Pediatric Infectious Diseases Society"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1326784","article-title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","volume":"18","author":"Doran","year":"2024","journal-title":"Frontiers in Neuroscience"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib84","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40478-024-01868-y","article-title":"Hyperspectral retinal imaging in Alzheimer\u2019s disease and age-related macular degeneration: A review","volume":"12","author":"Du","year":"2024","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108153","article-title":"Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer\u2019s disease","volume":"676","author":"Dubey","year":"2019","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.123171","article-title":"Bacopa monnieri reduces tau aggregation and Tau-mediated toxicity in cells","volume":"234","author":"Dubey","year":"2023","journal-title":"International Journal of Biological Macromolecules"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112970","article-title":"The inhibitory effect of Curcumin-Artemisinin co-amorphous on tau aggregation and tau phosphorylation","volume":"221","author":"Dubey","year":"2023","journal-title":"Colloids and Surfaces. B, Biointerfaces"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13195-023-01314-6","article-title":"Biomarkers in Alzheimer\u2019s disease: Role in early and differential diagnosis and recognition of atypical variants","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib89","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/1039856218762308","article-title":"Alzheimer\u2019s disease: Clinical update on epidemiology, pathophysiology and diagnosis","volume":"26","author":"Eratne","year":"2018","journal-title":"Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib90","series-title":"Neurochemical aspects of Alzheimer\u2019s disease","first-page":"331","article-title":"Chapter 9 - immunotherapy for the treatment of Alzheimer\u2019s disease","author":"Farooqui","year":"2017"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib91","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41541-024-00942-9","article-title":"A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer\u2019s disease in 3xTg mice","volume":"9","author":"Feng","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib92","article-title":"Microstructural mapping of neural pathways in Alzheimer\u2019s disease using macrostructure-informed normative tractometry","author":"Feng","year":"2024","journal-title":"bioRxiv"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.10.002_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/biom12111676","article-title":"Linking the amyloid, tau, and mitochondrial hypotheses of Alzheimer\u2019s disease and identifying promising drug targets","volume":"12","author":"Fi\u0161ar","year":"2022","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.10.002_bib94","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer\u2019s disease: Results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib95","article-title":"Immunological dimensions of neuroinflammation and microglial activation: Exploring innovative immunomodulatory approaches to mitigate neuroinflammatory progression","volume":"14","author":"Fornari Laurindo","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"159","key":"10.1016\/bs.apcsb.2025.10.002_bib96","doi-asserted-by":"crossref","first-page":"20190356","DOI":"10.1098\/rsif.2019.0356","article-title":"Prion-like spreading of Alzheimer\u2019s disease within the brain\u2019s connectome","volume":"16","author":"Fornari","year":"2019","journal-title":"Journal of the Royal Society, Interface \/ the Royal Society"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib97","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/alz.13490","article-title":"Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer\u2019s disease: Evidence from clinical and preclinical studies","volume":"20","author":"Gaikwad","year":"2024","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"10","key":"10.1016\/bs.apcsb.2025.10.002_bib98","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024331","article-title":"Antibody therapeutics targeting A\u03b2 and tau","volume":"7","author":"Gallardo","year":"2017","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.10.002_bib99","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.14283\/jpad.2024.163","article-title":"Phase 1 studies of the anti-Tau monoclonal antibody JNJ-63733657 in healthy participants and participants with Alzheimer\u2019s disease","volume":"11","author":"Galpern","year":"2024","journal-title":"Journal of Prevention of Alzheimer\u2019s Disease"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2023.137532","article-title":"Alzheimer\u2019s disease: The role of proteins in formation, mechanisms, and new therapeutic approaches","volume":"817","author":"Gholami","year":"2023","journal-title":"Neuroscience Letters"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib101","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2147\/NDT.S84266","article-title":"Role of apolipoprotein e in neurodegenerative diseases","volume":"11","author":"Giau","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"6248","key":"10.1016\/bs.apcsb.2025.10.002_bib102","doi-asserted-by":"crossref","DOI":"10.1126\/science.1255555","article-title":"NEURODEGENERATION. Alzheimer\u2019s and Parkinson\u2019s diseases: The prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein","volume":"349","author":"Goedert","year":"2015","journal-title":"Science (New York, N. Y.)"},{"issue":"16","key":"10.1016\/bs.apcsb.2025.10.002_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168947","article-title":"The role of fc receptors on the effectiveness of therapeutic monoclonal antibodies","volume":"22","author":"Gogesch","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.10.002_bib104","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/GIM.0b013e31821d69b8","article-title":"Genetic counseling and testing for alzheimer disease: Joint practice guidelines of the American college of medical genetics and The National society of genetic counselors","volume":"13","author":"Goldman","year":"2011","journal-title":"Genetics in Medicine: Official Journal of the American College of Medical Genetics"},{"issue":"23","key":"10.1016\/bs.apcsb.2025.10.002_bib105","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/092986708785909111","article-title":"Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease","volume":"15","author":"Gong","year":"2008","journal-title":"Current Medicinal Chemistry"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.10.002_bib106","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s10571-020-00897-0","article-title":"Autophagic pathways to clear the tau aggregates in Alzheimer\u2019s disease","volume":"41","author":"Gorantla","year":"2021","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib107","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.ijbiomac.2019.11.176","article-title":"Transition metal nickel prevents tau aggregation in Alzheimer\u2019s disease","volume":"156","author":"Gorantla","year":"2020","journal-title":"International Journal of Biological Macromolecules"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib108","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1038\/s41598-020-60773-1","article-title":"Basic limonoid modulates chaperone-mediated proteostasis and dissolve tau fibrils","volume":"10","author":"Gorantla","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-4939-6598-4_2","article-title":"Global conformation of tau protein mapped by Raman spectroscopy","volume":"1523","author":"Gorantla","year":"2017","journal-title":"Methods in Molecular Biology"},{"issue":"16","key":"10.1016\/bs.apcsb.2025.10.002_bib110","doi-asserted-by":"crossref","first-page":"16702","DOI":"10.1021\/acsomega.9b00692","article-title":"Molecular Cobalt(II) complexes for tau polymerization in Alzheimer\u2019s disease","volume":"4","author":"Gorantla","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-6598-4_1","article-title":"Conformational dynamics of intracellular tau protein revealed by CD and SAXS","volume":"1523","author":"Gorantla","year":"2017","journal-title":"Methods in Molecular Biology"},{"issue":"17","key":"10.1016\/bs.apcsb.2025.10.002_bib112","doi-asserted-by":"crossref","first-page":"11131","DOI":"10.1021\/acsomega.9b03497","article-title":"Amyloid-\u03b2-derived peptidomimetics inhibits tau aggregation","volume":"6","author":"Gorantla","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103691","article-title":"Antisense oligonucleotides for Alzheimer\u2019s disease therapy: From the mRNA to miRNA paradigm","volume":"74","author":"Grabowska-Pyrzewicz","year":"2021","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.10.002_bib114","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","article-title":"New insights into atypical Alzheimer\u2019s disease in the era of biomarkers","volume":"20","author":"Graff-Radford","year":"2021","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib115","series-title":"A comprehensive guide to toxicology in nonclinical drug development","first-page":"709","article-title":"Chapter 27 - preclinical toxicology of Vaccines11Disclaimer: The findings and conclusions in this chapter have not been formally disseminated by the food and drug administration and should not be construed to represent any agency determination or policy","author":"Green","year":"2017"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib116","doi-asserted-by":"crossref","first-page":"20s","DOI":"10.2967\/jnumed.121.263196","article-title":"Tau PET imaging in neurodegenerative disorders","volume":"63","author":"Groot","year":"2022","journal-title":"Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib117","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.phrs.2015.08.003","article-title":"Vaccines, adjuvants and autoimmunity","volume":"100","author":"Guimar\u00e3es","year":"2015","journal-title":"Pharmacological Research: the Official Journal of the Italian Pharmacological Society"},{"issue":"s1","key":"10.1016\/bs.apcsb.2025.10.002_bib118","doi-asserted-by":"crossref","first-page":"S611","DOI":"10.3233\/JAD-179935","article-title":"Role of amyloid-\u03b2 and tau proteins in Alzheimer\u2019s disease: Confuting the amyloid cascade","volume":"64","author":"Gulisano","year":"2018","journal-title":"Journal of Alzheimer\u2019s Disease: JAD"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102192","article-title":"Passive immunotherapy for Alzheimer\u2019s disease","volume":"94","author":"Guo","year":"2024","journal-title":"Ageing Research Reviews"},{"issue":"19","key":"10.1016\/bs.apcsb.2025.10.002_bib120","article-title":"Tau forms oligomeric complexes on microtubules that are distinct from tau aggregates","volume":"118","author":"Gyparaki","year":"2021","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.10.002_bib121","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1021\/acs.jmedchem.5b00220","article-title":"Combining active immunization with monoclonal antibody therapy to facilitate early initiation of a long-acting anti-methamphetamine antibody response","volume":"58","author":"Hambuchen","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.10.002_bib122","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): Radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"10","key":"10.1016\/bs.apcsb.2025.10.002_bib123","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-\u03b2 pathway in Alzheimer\u2019s disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Molecular Psychiatry"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib124","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/1673-5374.286965","article-title":"Dual targeting nano-approaches for Alzheimer\u2019s disease etiology","volume":"16","author":"Hettiarachchi","year":"2021","journal-title":"Neural Regeneration Research"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","article-title":"\u03b3-Secretase in Alzheimer\u2019s disease","volume":"54","author":"Hur","year":"2022","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib126","series-title":"A comprehensive guide to phase 1 clinical trials","author":"ICON","year":"2024"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib127","unstructured":"India,\u00a0R.R.F.M.A.I. (2016).\u00a0Guidelines on similar biologics. https:\/\/ibkp.dbtindia.gov.in\/DBT_Content_Test\/CMS\/Guidelines\/20181115140059519_Guidelines-on-Similar-Biologics-2016.pdf."},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00401-009-0486-3","article-title":"Mechanisms of tau-induced neurodegeneration","volume":"118","author":"Iqbal","year":"2009","journal-title":"Acta Neuropathologica"},{"issue":"8","key":"10.1016\/bs.apcsb.2025.10.002_bib129","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2174\/156720510793611592","article-title":"Tau in Alzheimer disease and related tauopathies","volume":"7","author":"Iqbal","year":"2010","journal-title":"Current Alzheimer Research"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","article-title":"A walk through tau therapeutic strategies","volume":"7","author":"Jadhav","year":"2019","journal-title":"Acta Neuropathologica Communications"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.10.002_bib131","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.7326\/M21-2918","article-title":"U.S. Food and drug administration reasoning in approval decisions when efficacy evidence is borderline, 2013-2018","volume":"174","author":"Janiaud","year":"2021","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib132","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-61779-551-0_7","article-title":"Conformations of microtubule-associated protein tau mapped by fluorescence resonance energy transfer","volume":"849","author":"Jeganathan","year":"2012","journal-title":"Methods in Molecular Biology"},{"issue":"46","key":"10.1016\/bs.apcsb.2025.10.002_bib133","doi-asserted-by":"crossref","first-page":"32066","DOI":"10.1074\/jbc.M805300200","article-title":"Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of tau and generates a pathological (MC-1) conformation","volume":"283","author":"Jeganathan","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"issue":"8","key":"10.1016\/bs.apcsb.2025.10.002_bib134","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3348\/kjr.2024.0105","article-title":"Amyloid-related imaging abnormalities in the era of Anti-Amyloid beta monoclonal antibodies for Alzheimer\u2019s disease: Recent updates on clinical and imaging features and MRI monitoring","volume":"25","author":"Jeong","year":"2024","journal-title":"Korean Journal of Radiology: Official Journal of the Korean Radiological Society"},{"issue":"10","key":"10.1016\/bs.apcsb.2025.10.002_bib135","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-021-01546-6","article-title":"Current status of clinical trials on tau immunotherapies","volume":"81","author":"Ji","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib136","doi-asserted-by":"crossref","first-page":"a006213","DOI":"10.1101\/cshperspect.a006213","article-title":"Brain imaging in Alzheimer disease","volume":"2","author":"Johnson","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.10.002_bib137","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1089\/brain.2019.0676","article-title":"Differentiation of early Alzheimer\u2019s disease, mild cognitive impairment, and cognitively healthy elderly samples using multimodal neuroimaging indices","volume":"9","author":"Joshi","year":"2019","journal-title":"Brain Connect"},{"issue":"S10","key":"10.1016\/bs.apcsb.2025.10.002_bib138","article-title":"Diversity in phase 2 and phase 3 Placebo-controlled, double-blind, lecanemab and elenbecestat early Alzheimer\u2019s disease studies","volume":"18","author":"Joshua Grill","year":"2022","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"24","key":"10.1016\/bs.apcsb.2025.10.002_bib139","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1073\/pnas.1504081112","article-title":"Tau stabilizes microtubules by binding at the interface between tubulin heterodimers","volume":"112","author":"Kadavath","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib140","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ng0895-486","article-title":"APOE\u204e4-associated Alzheimer\u2019s disease risk is modified by alpha 1-antichymotrypsin polymorphism","volume":"10","author":"Kamboh","year":"1995","journal-title":"Nature Genetics"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.10.002_bib141","article-title":"Clinical trials and clinical research: A comprehensive review","volume":"15","author":"Kandi","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib142","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","article-title":"ApoE and A\u03b2 in Alzheimer\u2019s disease: Accidental encounters or partners?","volume":"81","author":"Kanekiyo","year":"2014","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib143","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12974-023-02751-8","article-title":"TGF-\u03b21 signalling in Alzheimer\u2019s pathology and cytoskeletal reorganization: A specialized tau perspective","volume":"20","author":"Kapoor","year":"2023","journal-title":"Journal of Neuroinflammation"},{"issue":"10","key":"10.1016\/bs.apcsb.2025.10.002_bib144","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/alz.12620","article-title":"Moving beyond disclosure: Stages of care in preclinical Alzheimer\u2019s disease biomarker testing","volume":"18","author":"Ketchum","year":"2022","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.10.002_bib145","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2174\/1570159X18666200528142429","article-title":"Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer\u2019s disease","volume":"18","author":"Khan","year":"2020","journal-title":"Current Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib146","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12877-021-02109-w","article-title":"Behavioural and psychological symptoms of dementia in patients with Alzheimer\u2019s disease and family caregiver burden: A path analysis","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Geriatrics"},{"issue":"14","key":"10.1016\/bs.apcsb.2025.10.002_bib147","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1212\/WNL.0000000000207438","article-title":"Implications of the approval of lecanemab for alzheimer disease patient care: Incremental step or paradigm shift?","volume":"101","author":"Knopman","year":"2023","journal-title":"Neurology"},{"issue":"11-12","key":"10.1016\/bs.apcsb.2025.10.002_bib148","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10354-021-00819-9","article-title":"Genetics of Alzheimer\u2019s disease","volume":"171","author":"K\u00f6nig","year":"2021","journal-title":"Wiener Medizinische Wochenschrift (1946)"},{"issue":"12","key":"10.1016\/bs.apcsb.2025.10.002_bib149","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126442","article-title":"Brain disposition of antibody-based therapeutics: Dogma, approaches and perspectives","volume":"22","author":"Kouhi","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib150","series-title":"Alzheimer disease","author":"Kumar","year":"2024"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.10.002_bib151","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s13311-020-00853-2","article-title":"Immunotherapies for aging-related neurodegenerative diseases-emerging perspectives and new targets","volume":"17","author":"Kwon","year":"2020","journal-title":"Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib152","unstructured":"Laboratories,\u00a0A.\u00a0(2021). Apolipoprotein E (APOE) Genotyping, Alzheimer Disease Risk. https:\/\/arupconsult.com\/ati\/apolipoprotein-e-apoe-genotyping-alzheimer-disease-risk."},{"key":"10.1016\/bs.apcsb.2025.10.002_bib153","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1326-6-39","article-title":"Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice","volume":"6","author":"Lasagna-Reeves","year":"2011","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib154","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nbd.2015.05.004","article-title":"Fluid biomarkers in multiple system atrophy: a review of the MSA biomarker initiative","volume":"80","author":"Laurens","year":"2015","journal-title":"Neurobiology of Disease"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib155","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1074\/jbc.M002466200","article-title":"Indirubins inhibit glycogen synthase kinase-3 beta and CDK5\/p25, two protein kinases involved in abnormal tau phosphorylation in alzheimer\u2019s disease. A property common to most cyclin-dependent kinase inhibitors?","volume":"276","author":"Leclerc","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.10.002_bib156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0250-2","article-title":"Diagnosis of Alzheimer\u2019s disease utilizing amyloid and tau as fluid biomarkers","volume":"51","author":"Lee","year":"2019","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib157","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fnmol.2019.00158","article-title":"Diverse misfolded conformational strains and cross-seeding of misfolded proteins implicated in neurodegenerative diseases","volume":"12","author":"Lim","year":"2019","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.10.002_bib158","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nature Reviews Neurology"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib159","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40035-024-00397-x","article-title":"The interaction between ageing and Alzheimer\u2019s disease: Insights from the hallmarks of ageing","volume":"13","author":"Liu","year":"2024","journal-title":"Transl Neurodegener"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib160","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1887628","article-title":"Off-target binding of an anti-amyloid beta monoclonal antibody to platelet factor 4 causes acute and chronic toxicity in cynomolgus monkeys","volume":"13","author":"Loberg","year":"2021","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib161","first-page":"873","article-title":"Antibody-mediated clearance of brain amyloid-\u03b2: Mechanisms of action, effects of natural and monoclonal anti-A\u03b2 antibodies, and downstream effects","volume":"7","author":"Loeffler","year":"2023","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib162","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.692040","article-title":"The mammalian family of katanin microtubule-severing enzymes","volume":"9","author":"Lynn","year":"2021","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.10.002_bib163","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1755-5949.2010.00177.x","article-title":"The role of tau in Alzheimer\u2019s disease and related disorders","volume":"17","author":"Medeiros","year":"2011","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.10.002_bib164","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.3390\/ijms15034671","article-title":"Tau protein modifications and interactions: Their role in function and dysfunction","volume":"15","author":"Mietelska-Porowska","year":"2014","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib165","article-title":"Association between the APOE \u03b54 allele and late-onset alzheimer\u2019s disease in an Ecuadorian mestizo population","volume":"2017","author":"Montufar","year":"2017","journal-title":"International Journal of Alzheimer\u2019s Disease"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.10.002_bib166","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer\u2019s disease: A phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib167","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10571-020-00883-6","article-title":"Role of microglia in regulating cholesterol and tau pathology in Alzheimer\u2019s disease","volume":"41","author":"Nanjundaiah","year":"2021","journal-title":"Cellular and Molecular Neurobiology"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib168","first-page":"43","article-title":"Alzheimer\u2019s disease puzzle: Delving into pathogenesis hypotheses","volume":"15","author":"Nasb","year":"2024","journal-title":"Aging and Disease"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib169","article-title":"Tau oligomers neurotoxicity","volume":"11","author":"Niewiadomska","year":"2021","journal-title":"Life (Basel)"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.10.002_bib170","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ajpath.2017.01.022","article-title":"Tau antibody targeting pathological species blocks neuronal uptake and interneuron propagation of tau in vitro","volume":"187","author":"Nobuhara","year":"2017","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib171","unstructured":"Organization,\u00a0C.D.S.C. (2024). India. Central Drugs Standard Control Organization. https:\/\/clinregs.niaid.nih.gov\/country\/india#."},{"key":"10.1016\/bs.apcsb.2025.10.002_bib172","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/B978-0-323-98817-9.00029-6","article-title":"Passive tau-based immunotherapy for tauopathies","volume":"196","author":"Panza","year":"2023","journal-title":"Handbook of Clinical Neurology"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib173","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1053\/j.seminoncol.2016.07.002","article-title":"Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development","volume":"43","author":"Parchment","year":"2016","journal-title":"Seminars in Oncology"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib174","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2023.1227816","article-title":"Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier","volume":"3","author":"Pardridge","year":"2023","journal-title":"Frontiers in Drug Delivery"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.10.002_bib175","first-page":"Cd009081","article-title":"Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia","volume":"2","author":"Parsons","year":"2021","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib176","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010778","article-title":"Apoe4 and Alzheimer\u2019s disease pathogenesis-mitochondrial deregulation and targeted therapeutic strategies","volume":"24","author":"Pires","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105010","article-title":"Passive immunotherapies targeting A\u03b2 and tau in Alzheimer\u2019s disease","volume":"144","author":"Plotkin","year":"2020","journal-title":"Neurobiology of Disease"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib178","doi-asserted-by":"crossref","first-page":"437","DOI":"10.31887\/DCNS.2016.18.4\/cepperson","article-title":"Considering sex and gender in alzheimer disease and other dementias","volume":"18","author":"Podcasy","year":"2016","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.10.002_bib179","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/alzrt214","article-title":"Propagation of tau pathology in Alzheimer\u2019s disease: Identification of novel therapeutic targets","volume":"5","author":"Pooler","year":"2013","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.10.002_bib180","doi-asserted-by":"crossref","first-page":"371","DOI":"10.14283\/jpad.2021.23","article-title":"Diagnosis of early Alzheimer\u2019s disease: Clinical practice in 2021","volume":"8","author":"Porsteinsson","year":"2021","journal-title":"Journal of Prevention of Alzheimer\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib181","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/cts.12855","article-title":"Model informed dosing regimen and phase I results of the Anti-PD-1 antibody budigalimab (ABBV-181)","volume":"14","author":"Powderly","year":"2021","journal-title":"Clinical and Translational Science"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib182","unstructured":"Queensland,\u00a0H.T. (2024).\u00a0Understanding the clinical trial phases 2024. Health Translation Queensland. Retrieved 18\u00a0July\u00a0from https:\/\/clinicaltrialshub.htq.org.au\/blog\/understanding-the-clinical-trial-phases\/."},{"key":"10.1016\/bs.apcsb.2025.10.002_bib183","series-title":"Advances in protein chemistry and structural biology","article-title":"Nuclear podosomes regulates cellular migration in tau and Alzheimer\u2019s disease","author":"Qureshi","year":"2024"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib184","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JAD-160612","article-title":"Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons","volume":"57","author":"Rajmohan","year":"2017","journal-title":"Journal of Alzheimer\u2019s Disease: JAD"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib185","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1590\/1980-57642015DN94000356","article-title":"Dementia resulting from traumatic brain injury","volume":"9","author":"Ramalho","year":"2015","journal-title":"Dement Neuropsychol."},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib186","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13024-023-00637-0","article-title":"Anti-amyloid therapies for Alzheimer disease: Finally, good news for patients","volume":"18","author":"Ramanan","year":"2023","journal-title":"Molecular Neurodegeneration"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib187","article-title":"Donanemab for alzheimer\u2019s disease: A systematic review of clinical trials","volume":"11","author":"Rashad","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib188","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","article-title":"ApoE in Alzheimer\u2019s disease: Pathophysiology and therapeutic strategies","volume":"17","author":"Raulin","year":"2022","journal-title":"Molecular Neurodegeneration"},{"issue":"21","key":"10.1016\/bs.apcsb.2025.10.002_bib189","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112841","article-title":"Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies","volume":"23","author":"Rawat","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2024.112620","article-title":"Non pharmacoligical approaches for neurodegenerative diseases: A narrative review","volume":"198","author":"Raza","year":"2024","journal-title":"Experimental Gerontology"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.10.002_bib191","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063245","article-title":"Physical exercise, a potential non-pharmacological intervention for attenuating neuroinflammation and cognitive decline in Alzheimer\u2019s disease patients","volume":"23","author":"Ribari\u010d","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib192","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jsbmb.2016.03.012","article-title":"Age, APOE and sex: Triad of risk of Alzheimer\u2019s disease","volume":"160","author":"Riedel","year":"2016","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.10.002_bib193","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.neurobiolaging.2013.03.015","article-title":"Tau phosphorylation affects its axonal transport and degradation","volume":"34","author":"Rodr\u00edguez-Mart\u00edn","year":"2013","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib194","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.872171","article-title":"Comprehensive characterization of CK1\u03b4-Mediated tau phosphorylation in Alzheimer\u2019s disease","volume":"9","author":"Roth","year":"2022","journal-title":"Frontiers in Molecular Biosciences"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.10.002_bib195","first-page":"Cd009132","article-title":"Cholinesterase inhibitors for mild cognitive impairment","volume":"2012","author":"Russ","year":"2012","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib196","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000369101","article-title":"Amyloid-beta: A crucial factor in Alzheimer\u2019s disease","volume":"24","author":"Sadigh-Eteghad","year":"2015","journal-title":"Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.10.002_bib197","first-page":"401","article-title":"Advances in diagnostic testing for alzheimer disease","volume":"110","author":"Schindler","year":"2013","journal-title":"Missouri Medicine"},{"issue":"10","key":"10.1016\/bs.apcsb.2025.10.002_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanhl.2024.07.013","article-title":"Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease","volume":"5","author":"Sch\u00f6ll","year":"2024","journal-title":"Lancet Healthy Longevity"},{"issue":"12","key":"10.1016\/bs.apcsb.2025.10.002_bib199","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243535","article-title":"Olfactory response as a marker for Alzheimer\u2019s disease: Evidence from perceptual and frontal lobe oscillation coherence deficit","volume":"15","author":"Sedghizadeh","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib200","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","article-title":"APOE and Alzheimer\u2019s disease: Advances in genetics, pathophysiology, and therapeutic approaches","volume":"20","author":"Serrano-Pozo","year":"2021","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib201","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fnagi.2017.00083","article-title":"Tau oligomers: Cytotoxicity, propagation, and mitochondrial damage","volume":"9","author":"Shafiei","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib202","series-title":"Design and analysis of clinical trials: Concepts and methodologies","author":"Shein-Chung Chow","year":"2013"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib203","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13195-022-01150-0","article-title":"Alpha-synuclein: A pathological factor with A\u03b2 and tau and biomarker in Alzheimer\u2019s disease","volume":"14","author":"Shim","year":"2022","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"s1","key":"10.1016\/bs.apcsb.2025.10.002_bib204","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.3233\/JAD-179937","article-title":"Tau immunotherapies for Alzheimer\u2019s disease and related tauopathies: Progress and potential pitfalls","volume":"64","author":"Sigurdsson","year":"2018","journal-title":"Journal of Alzheimer\u2019s Disease: JAD"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.10.002_bib205","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA: the Journal of the American Medical Association"},{"issue":"21","key":"10.1016\/bs.apcsb.2025.10.002_bib206","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12216792","article-title":"Anti-amyloid therapy, AD, and ARIA: Untangling the role of CAA","volume":"12","author":"Sin","year":"2023","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib207","series-title":"Cholinesterase inhibitors","author":"Singh","year":"2024"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib208","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1741134312466560","article-title":"India: similar biologics guidelines and implementation","volume":"9","author":"Singhania","year":"2012","journal-title":"Journal of Generic Medicines"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108119","article-title":"Baicalein suppresses repeat tau fibrillization by sequestering oligomers","volume":"675","author":"Sonawane","year":"2019","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib210","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69429-6","article-title":"EGCG impedes human tau aggregation and interacts with tau","volume":"10","author":"Sonawane","year":"2020","journal-title":"Scientific Reports"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.10.002_bib211","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.18632\/oncotarget.27963","article-title":"Epigallocatechin-3-gallate modulates tau post-translational modifications and cytoskeletal network","volume":"12","author":"Sonawane","year":"2021","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib212","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12964-021-00704-3","article-title":"Baicalein inhibits heparin-induced tau aggregation by initializing non-toxic tau oligomer formation","volume":"19","author":"Sonawane","year":"2021","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib213","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","article-title":"Immunotherapy for Alzheimer\u2019s disease: Targeting \u03b2-amyloid and beyond","volume":"11","author":"Song","year":"2022","journal-title":"Translational Neurodegeneration"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105120","article-title":"Characterization of tau binding by gosuranemab","volume":"146","author":"Sopko","year":"2020","journal-title":"Neurobiology of Disease"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.10.002_bib215","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from The National institute on aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib216","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s association research roundtable workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib217","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","article-title":"The intersection of amyloid beta and tau at synapses in Alzheimer\u2019s disease","volume":"82","author":"Spires-Jones","year":"2014","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.10.002_bib218","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-015-1413-4","article-title":"Templated misfolding of tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in tau transgenic mice","volume":"129","author":"Stancu","year":"2015","journal-title":"Acta Neuropathologica"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.10.002_bib219","article-title":"Identification of Alzheimer\u2019s disease by imaging: A comprehensive review","volume":"20","year":"2023","journal-title":"International Journal of Environmental Research and Public Health"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib220","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.46179","article-title":"Family history of Alzheimer\u2019s disease alters cognition and is modified by medical and genetic factors","volume":"8","author":"Talboom","year":"2019","journal-title":"Elife"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.10.002_bib221","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa099","article-title":"Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology","volume":"2","author":"Tanabe","year":"2020","journal-title":"Brain Communications"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib222","unstructured":"TD, B. (1998, 2018 Dec 20). Alzheimer Disease Overview. GeneReviews\u00ae [Internet]. Retrieved 23 October from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1161\/#:\u223c:text=While%20the%20association%20of%20the,isoforms%20of%20the%20protein%20ApoE."},{"issue":"8","key":"10.1016\/bs.apcsb.2025.10.002_bib223","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease: A randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurology"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib224","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3233\/JAD-161088","article-title":"Oxidative stress, synaptic dysfunction, and Alzheimer\u2019s disease","volume":"57","author":"T\u00f6nnies","year":"2017","journal-title":"Journal of Alzheimer\u2019s Disease: JAD"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.10.002_bib225","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3233\/JAD-2010-1271","article-title":"Tau phosphorylated at tyrosine 394 is found in Alzheimer\u2019s disease tangles and can be a product of the Abl-related kinase, arg","volume":"19","author":"Tremblay","year":"2010","journal-title":"Journal of Alzheimer\u2019s Disease: JAD"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.10.002_bib226","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076518","article-title":"Inflammatory processes in Alzheimer\u2019s disease-pathomechanism, diagnosis and treatment: A review","volume":"24","author":"Twarowski","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib227","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","article-title":"\u03b1-Synuclein in the pathophysiology of Alzheimer\u2019s disease","volume":"14","author":"Twohig","year":"2019","journal-title":"Molecular Neurodegeneration"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.10.002_bib228","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2013.01.013","article-title":"Immunotherapy for neurodegenerative diseases: Focus on \u03b1-synucleinopathies","volume":"138","author":"Valera","year":"2013","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib229","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","article-title":"Immunotherapeutic approaches targeting amyloid-\u03b2, \u03b1-Synuclein, and tau for the treatment of neurodegenerative disorders","volume":"13","author":"Valera","year":"2016","journal-title":"Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib230","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer\u2019s disease: Pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib231","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","article-title":"Active A\u03b2 immunotherapy CAD106 in Alzheimer\u2019s disease: A phase 2b study","volume":"3","author":"Vandenberghe","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib232","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fnmol.2019.00107","article-title":"Spreading of \u03b1-synuclein and tau: A systematic comparison of the mechanisms involved","volume":"12","author":"Vasili","year":"2019","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib233","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/CIA.S325026","article-title":"Role of aducanumab in the treatment of Alzheimer\u2019s disease: Challenges and opportunities","volume":"17","author":"Vaz","year":"2022","journal-title":"Clinical Interventions in Aging"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib234","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer\u2019s disease: Recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.10.002_bib235","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathologica"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib236","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043895","article-title":"Alzheimer\u2019s disease: A brief history of immunotherapies targeting amyloid \u03b2","volume":"24","author":"Vogt","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib237","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41392-022-01211-8","article-title":"Epigenetic regulation of aging: Implications for interventions of aging and diseases","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"35","key":"10.1016\/bs.apcsb.2025.10.002_bib238","doi-asserted-by":"crossref","first-page":"27302","DOI":"10.1074\/jbc.M110.145318","article-title":"Human tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability","volume":"285","author":"Wegmann","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib239","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt237","article-title":"Active immunotherapy options for Alzheimer\u2019s disease","volume":"6","author":"Winblad","year":"2014","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib240","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s40001-023-01512-w","article-title":"The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wu","year":"2023","journal-title":"European Journal of Medical Research"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib241","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00401-024-02696-z","article-title":"The contribution of \u03b2-amyloid, tau and \u03b1-synuclein to blood-brain barrier damage in neurodegenerative disorders","volume":"147","author":"Wu","year":"2024","journal-title":"Acta Neuropathologica"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.10.002_bib242","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13111554","article-title":"Investigation of the relationship between apolipoprotein e alleles and serum lipids in Alzheimer\u2019s disease: A meta-analysis","volume":"13","author":"Xu","year":"2023","journal-title":"Brain Sciences"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.10.002_bib243","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s13311-023-01405-0","article-title":"Anti-amyloid immunotherapies for Alzheimer\u2019s disease: A 2023 clinical update","volume":"20","author":"Yadollahikhales","year":"2023","journal-title":"Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.10.002_bib244","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","article-title":"Apolipoprotein E and Alzheimer disease: Pathobiology and targeting strategies","volume":"15","author":"Yamazaki","year":"2019","journal-title":"Nature Reviews Neurology"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.10.002_bib245","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/1567205012666150204121719","article-title":"Role of environmental contaminants in the etiology of alzheimer\u2019s disease: A review","volume":"12","author":"Yegambaram","year":"2015","journal-title":"Current Alzheimer Research"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib246","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.912995","article-title":"Mouse models of Alzheimer\u2019s disease","volume":"15","author":"Yokoyama","year":"2022","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.10.002_bib247","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s13311-013-0187-4","article-title":"Developing therapeutic antibodies for neurodegenerative disease","volume":"10","author":"Yu","year":"2013","journal-title":"Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib248","article-title":"Role of A\u03b2 in Alzheimer\u2019s-related synaptic dysfunction","volume":"10","author":"Zhang","year":"2022","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"1(1","key":"10.1016\/bs.apcsb.2025.10.002_bib249","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1471-4159.2011.07519.x","article-title":"Proteolytic processing of Alzheimer\u2019s \u03b2-amyloid precursor protein","volume":"120","author":"Zhang","year":"2012","journal-title":"Journal of Neurochemistry"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.10.002_bib250","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.7150\/ijbs.57078","article-title":"Interaction between A\u03b2 and tau in the pathogenesis of Alzheimer\u2019s disease","volume":"17","author":"Zhang","year":"2021","journal-title":"International Journal of Biological Sciences"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib251","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib252","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12979-024-00445-0","article-title":"Neuroinflammation in Alzheimer\u2019s disease: Insights from peripheral immune cells","volume":"21","author":"Zhang","year":"2024","journal-title":"Immunity & Ageing: I & A"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib253","doi-asserted-by":"crossref","DOI":"10.3389\/bjbs.2024.13169","article-title":"Neuronal vulnerability of the entorhinal cortex to tau pathology in Alzheimer\u2019s disease","volume":"81","author":"Zhang","year":"2024","journal-title":"British Journal of Biomedical Science"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib254","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.actbio.2024.06.001","article-title":"Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer\u2019s disease","volume":"183","author":"Zhang","year":"2024","journal-title":"Acta Biomaterialia"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib255","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: Challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.10.002_bib256","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24751","article-title":"The molecular mechanism of aging and the role in neurodegenerative diseases","volume":"10","author":"Zhao","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/bs.apcsb.2025.10.002_bib257","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978513","article-title":"Applications of nanobodies in brain diseases","volume":"13","author":"Zheng","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.10.002_bib258","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40478-020-00948-z","article-title":"Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation","volume":"8","author":"Zilkova","year":"2020","journal-title":"Acta Neuropathologica Communications"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Immunomodulators - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162325000896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162325000896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:45:06Z","timestamp":1779219906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162325000896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443345210"],"references-count":258,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2025.10.002","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}